StockNews.AI

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited)

StockNews.AI • 2 hours

ABMDMDGLNTRA
High Materiality9/10

Information

Estimated Q4 2025 Revenue of $28.8 million, an increase of 41%; Grew full-year revenue to an estimat...

Original source

AI Summary

Biodesix, Inc. (BDSX) announced impressive Q4 2025 results with a 41% revenue increase, totaling $28.8 million. The company anticipates positive Adjusted EBITDA for the quarter and remains optimistic about growth in Lung Diagnostics, likely benefiting its stock performance.

Sentiment Rationale

Significant revenue increases and positive EBITDA affirm the company's growth strategy. Similar past events in biotech firms have led to stock price rallies.

Trading Thesis

BDSX is a buy due to strong revenue growth and positive EBITDA outlook in Q4 2025.

Market-Moving

  • 41% revenue growth in Q4 could attract investor attention.
  • Affirmation of positive Adjusted EBITDA signals improving operational efficiency.
  • Increased cash position suggests financial stability for future investments.
  • Growth in Lung Diagnostics could enhance investor confidence.

Key Facts

  • BDSX reported Q4 2025 revenue of $28.8 million, up 41%.
  • Full-year 2025 revenue reached $88.5 million, a 24% increase.
  • Lung Diagnostics revenue for Q4 2025 was $25.2 million, increased 47%.
  • Company affirms positive Adjusted EBITDA for Q4 2025.
  • Cash and equivalents stood at $19.0 million by year-end 2025.

Companies Mentioned

  • Biodesix, Inc. (BDSX): Strong performance metrics could boost BDSX's market position.

Corporate Developments

This report fits the 'Corporate Developments' category as it details the company's financial performance and operational enhancements, which are critical for investor insights on BDSX’s future potential.

Biodesix (BDSX) Announces Strong Preliminary Q4 and Full-Year 2025 Results

Published on January 12, 2026

Financial Highlights for Q4 and Fiscal Year 2025

Biodesix, Inc. (Nasdaq: BDSX), a leader in diagnostic solutions, reported estimated preliminary revenues for the fourth quarter and full fiscal year 2025. The results reflect significant growth in both total and Lung Diagnostics revenues, marking a promising end to the year.

  • Q4 2025 Revenue: Estimated at $28.8 million, representing a 41% increase year-over-year.
  • Full-Year Revenue 2025: Estimated at $88.5 million, an increase of 24% compared to 2024.
  • Guidance: Positive Adjusted EBITDA anticipated for Q4 2025.

CEO Scott Hutton Comments on Performance

Scott Hutton, Chief Executive Officer of Biodesix, expressed optimism about the company’s performance in 2025. He stated, “Biodesix finished 2025 with a strong fourth quarter, delivering estimated revenue of $88.5 million, which exceeds the high end of our revised guidance of $84-$86 million.”

Hutton highlighted the specific drivers behind this growth, noting the increase in test volumes and the expansion of reimbursement frameworks, which contributed to accelerated revenue growth in Lung Diagnostics.

Dive Into Revenue Streams

Biodesix's progress can be further assessed by examining its key revenue streams:

  • Lung Diagnostics Revenue: Estimated at $25.2 million for Q4 and $79.2 million for FY 2025, with increases of 47% and 22%, respectively.
  • Test Volumes: Recorded at 18,000 and 62,600 tests for Q4 and FY 2025, marking increases of 23% and 15%.
  • Development Services Revenue: Estimated at $3.6 million for Q4 and $9.3 million for FY 2025, which reflects increases of 13% and 41%.
  • Cash Reserves: Biodesix reported cash and cash equivalents totaling $19.0 million at the end of 2025, a 14% increase from the previous quarter.

Looking Ahead: Expectations for 2026

Biodesix is committed to building upon its 2025 achievements with continued focus on its innovative diagnostic tests, including Nodify Lung® and IQLung®. The company is dedicated to enhancing clinical outcomes for patients and expects to further improve its revenue trajectories in the coming year.

About Biodesix

Biodesix is a premier diagnostic solutions company focused on improving clinical care and outcomes for patients suffering from lung diseases. Their advanced tests facilitate informed medical decisions and aim to enhance patient outcomes significantly.

Disclaimer

This release may contain forward-looking statements that involve substantial risks and uncertainties, as defined by the Private Securities Litigation Reform Act of 1995. Such statements rely on management’s expectations and projections regarding future events and are subject to various risks that may cause actual outcomes to differ significantly.

Related News